These mechanisms contribute to the establishment of an immunosuppressive tumor microenvironment, allowing cancer cells to evade immune surveillance, which suggests that targeting MYC could be a therapeutic strategy to counteract immune evasion and enhance cancer treatment outcomes. The gene discussed is MYC; the disease is cancer.